1. 1 100 ng/mL for decitabine. Plasma samples were collected on Day 1 of the first guadecitabine cycle. Samples Library Preparation and Sequencing 1. 1
1. 1 were collected before dosing and at 15, 30, 60, and 90 minutes, and 2, 4, 6, and 8 hours after the dose. 1. 2
Clinical Endpoints 1. 3
The primary endpoint was the MTD and safety of guadecitabine combined with ipilimumab. Secondary ir 1. 4 endpoints included ir-disease control rate (DCR) (confirmed ir-CR, -PR, or -SD), ir-ORR (ir-CR or-PR), time to 1. 5 response, duration of response, and progression free survival (PFS) (time between first dose and 1. 6 progression of existing lesions or the occurrence of new lesions); OS was also assessed. Exploratory 1. 7 endpoints included the pharmacokinetic profile of guadecitabine and decitabine at Cycle 1 Day 1, patient-1. 8 wise genome-wide DNA methylation and RNA sequencing, and analysis of the tumor immune contexture 1. 9 using neoplastic samples obtained by surgical removal or fine needle biopsy at baseline, Week 4 and Week 1. 10 12.
11
Isolation of total DNA 1. 12 A maximum amount of 25 mg of frozen tissue was placed in 1.5 ml microcentrifuge tubes containing 600 µl 1. 13 of Buffer RTL Plus and homogenized using the TissueLyser (Qiagen, Germany) for 1.5 min at 28 Hz. The 1. 14 position of TissueLyser set adapter was inverted to give uniform disruption and homogenization of the 1. 15 sample. Sample disruption was carried out at 4°C after storing the adapter set at -80°C for at least 2 h. 1. 16 Genomic DNA was extracted using QIAamp DNA Mini Kit (Qiagen Germany) according to the 1. 17 manufacturer's protocol. DNA concentration and quality were determined using the NanoDrop ND-1000 1. 18 UV-Vis Spectrophotometer (NanoDrop Technologies, Thermo Fisher Scientific DE, USA).
19

Library Preparation and Sequencing 1. 20
For reduced representation bisulfite sequencing (RRBS), 100 ng of genomic DNA were digested for 6 h at 1. 21 65°C with 20 U TaqI (New England Biolabs) and for 6 h at 37°C with 20 U of MspI (New England Biolabs) in 1. 22 preparation and adaptor ligation were performed in a single-tube setup. End fill-in and A-tailing were 1. 1 performed by addition of Klenow Fragment 3' & gt; 5' exo-(New England Biolabs); and dNTP mix (10 mM 1. 2 dATP, 1 mM dCTP, 1 mM dGTP). After ligation to methylated Illumina TruSeq LT v2 adaptors using T4 DNA 1. 3 Ligase rapid (Enzymatics), the libraries were size selected by performing a 0.75x clean-up with AMPure XP 1. 4 beads (Beckman Coulter). The libraries were pooled based on qPCR data and subjected to bisulfite 1. 5 conversion using the EZ DNA Methylation Direct Kit (Zymo Research) with changes to the manufacturer's 1. 6 protocol: conversion reagent was used at 0.9x concentration, incubation performed for 20 cycles of 1 min 1. 7 at 95°C and 10 min at 60°C, and the desulphonation time was extended to 30 min. These changes increase 1. 8 the number of CpG dinucleotides covered, by reducing double-strand break formation in larger library 1. 9 fragments. Bisulfite-converted libraries were enriched using APA HiFi HS Uracil+ RM (Roche). The minimum 1. 10 number of enrichment cycles was estimated based on a qPCR experiment. After a 1x AMPure XP clean-up, 1. 11 library concentrations were quantified with the Qubit Fluorometric Quantitation system (Life Technologies) 1. 12 and the size distribution was assessed using the Bioanalyzer High Sensitivity DNA Kit (Agilent To analyse the global methylation states, methylKit (25) and custom R scripts were used. Raw methylation 1. 6 level data on CpG sites were filtered such that only sites with a read coverage >10 and having a coverage 1. 7 not higher than the 99.9 percentile of all sites were retained. Furthermore, only CpG sites that were 1. 8 present in all samples (baseline, Week 4, Week 12) of an individual patient and had a reliable measurement 1. 9 methylation level were used for further analyses. To statistically test the methylation levels at each CpG site 1. 10 we calculated p-values as previously described (26). Sites with a probability of p <0.05 that their real 1. 11 methylation level lies outside a 0.1 error interval were considered reliable. Global methylation levels were 1. 12 calculated as mean and median methylation level of all retained CpG sites and plotted as density (beta-1. 13 binomial distribution) and box plots using ggplot2 (27). A Wilcoxon signed rank test with continuity 1. 14 correction was used to calculate p-values for comparing methylation level distribution at different time 1. 15 points.
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Isolation of total RNA and sequencing 1. 17
Total RNA was extracted by TRIzol Reagent (Thermo Fisher Scientific DE, USA). Frozen tissue was placed in 2 1. 18 ml microcentrifuge tubes containing 1 ml TRIzol reagent and homogenized using the TissueLyser (Qiagen, 1. 19
Germany) for 1.5 min at 28 Hz, as for DNA isolation. Total RNA extraction was done as previously described 1. 20 (Table 2) , and were more frequent in patients treated with guadecitabine 60 mg/m 2 /day (Table 3) ; no 1. 1 febrile neutropenia was observed. All ir-AEs were grade 1 or 2, and were most commonly skin or 1. 2 gastrointestinal toxicities (Table 2) . No DLTs were observed at any investigated dose of guadecitabine.
3
Treatment-related AEs and ir-AEs were generally manageable and reversible as per protocol management 1. 4 guidelines. One (14%) patient with grade 2 ir-colitis required steroid treatment; grade 3 or 4 myelotoxicity 1. 5 was treated with growth factors and prophylactic antibiotics. Median time to resolution of treatment-1. 6 related grade 2-4 AEs and of ir grade 1-2 AEs was 7 days (range 1-45 days) and 7 days (range 4-9 days), 1. 7 respectively.
8
Clinical activity and pharmacokinetics 1. 9
The ir-ORR was 5/19 (26%; 95% CI: 10.1-51.4) among them 2 confirmed CR and 3 confirmed PR, and ir-DCR 1. 10 was 8/19 (42%; 95% CI: 21.1-66.0); median time to response was 12 weeks and median duration of 1. 11 response was 25.4 months (95% CI: 10.4-40.4). At a median follow-up of 26.3 months, median PFS was 5.6 1. 12 months (95% CI: 4.5-6.6) and median OS was 26.2 months (95% CI: 3.5-48.9); one-and two-year OS rates 1. 13 were 80% (95% CI: 59.2-100.0) and 56% (95% CI: 29.0-83.0), respectively. 1. 14 Guadecitabine underwent efficient conversion to its active metabolite decitabine as seen by analysis of 1. 15 plasma exposure (data not shown); decitabine exposure as measured by area under the curve (AUC) 1. 16 increased in a dose-dependent manner ( Supplementary Table S1 ). 1. 17
Immunobiological activity 1. 18
To explore the immunobiological activity of guadecitabine combined with ipilimumab, serial tumor biopsies 1. 19 from the initial 8 and 11 patients treated were analysed for methylation and gene expression profiles, and 1. 20 for tumor immune contexture, respectively. The investigated tumor biopsies were derived from skin 1. 21 lesions, and from metastatic lymph-nodes for patient 7 at Week 4 and Week 12. RRBS of CpG sites 1. 22 demonstrated a significant reduction in global methylation in investigated tumor samples at Week 4 1. 23 Table S3 ). Medians of 49.4% (range: 17.4%-58.7%) and 53.9% (range: 1. 5 41.3%-62.7%) of DEG were up-regulated at Week 4 and Week 12, respectively ( Supplementary Table S3 ). Of 1. 6 the 136 canonical pathways that were significantly modulated according to ingenuity pathway analysis (IPA) 1. 7 (p<0.05 and Z-score ≥2 or Z-score ≤-2) at Week 4 or Week 12 compared to baseline in at least 1 patient, the 1. 8 most frequently activated (Z-score ≥2) were immune-related pathways ( Supplementary Table S4 ).
9
Specifically, iCOS-iCOSL signalling in T helper cells, PKCθ signalling in T lymphocytes, role of NFAT in 1. 10 regulation of the immune response, Th1, calcium-induced T lymphocyte apoptosis, IFN signalling pathways 1. 11
were activated in at least 5 investigated tumor samples, with frequency of activation ranging from 56 to 1. 12 71% ( Supplementary Table S4 ). 1. 13
Supervised differential expression analysis between responding and non-responding patients identified 1. 14 3104, 3920, and 3796 DEG at baseline, Week 4, and Week 12, respectively, the majority of which were up-1. 15 regulated in responders (data not shown). Th1 and Th2, dendritic cell maturation, calcium-induced T 1. 16 lymphocyte apoptosis, iCOS-iCOSL signalling in T helper cell, neuroinflammation signalling, cAMP-mediated 1. 17 signalling, and role of NFAT in regulation of the immune response pathways were significantly (p<0.05) 1. 18 activated (Z-score≥2) at baseline in responders vs non-responders ( Supplementary Fig.S1 , Supplementary 1. 19 Table S5 ). The absolute number of DEG belonging to these pathways increased with treatment and peaked 1. 20 at Week 12 ( Supplementary Fig. S1 ); furthermore, additional immune-related pathways (e.g., acute phase 1. 21 response, B cell receptor, NF-κB, and IL-2 signalling) were activated in responders vs non-responders at 1. 22
Week 4 and/or Week 12 ( Supplementary Fig. S1 , Supplementary Table S5 ). 3 (100%) c 1 (33%) 6 (100%) 6 (100%) 10 (100%) 9 (90%) 19 (100%) 16 (84%) Any treatmentrelated adverse event 2 (67%) 1 (33%) 6 (100%) 6 (100%) 10 (100%) 8 (80%) 18 (95%) 15 (79%) Fatigue/asthenia Nausea/vomiting Pain Myelotoxicity Neutropenia Leukopenia Thrombocytopenia Lymphocytopenia 0 2 (67%) 0 1 (33%) 1 (33%) 1 (33%) 0 1 (33%) 0 0 0 1 (33%) 1 (33%) 0 0 0 1 (17%) 1 (17%) 3 (50%) 6 (100%) 6 (100%) 2 (33%) 1 (17%) 1 (17%) 0 0 0 6 (100%) 6 (100%) 1 (17%) 0 1 (17%) 3 (30%) 1 (10%) 4 (40%) 10 (100%) 10 (100%) 9 (90%) 2 (20%) 4 (40%) Research.
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